More on ALPMY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $13.45 |
|
|||
| Open | $13.48 | ||||
| 52 Wk High | $19.40 | ||||
| 52 Wk Low | $12.50 | ||||
| Day High | $13.56 | ||||
| Day Low | $13.45 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 380,312 | ||||
- Goldman Sachs Reiterates Buy Rating on Astellas Pharma Inc (4503:JP) (ALPMY)
- Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,600 at Macquarie
- Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company
- Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
- "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
- Astellas reports IZERVAY reduced driving eligibility loss risk in eye disease study
- IZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patients
- Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,400 at Citi
- Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,400 at Citi
- Astellas to Highlight New Findings for Geographic Atrophy at ARVO 2026 Annual Meeting
Entities mentioned with ALPMY
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- PDUFA | View Related Stories »
- S1 | View Related Stories »
- S3 | View Related Stories »
- ARK | View Related Stories »
- Show More...
